End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14,750 KRW | +0.14% | +1.17% | -5.81% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company shows low valuation levels, with an enterprise value at 498.62 times its sales.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.81% | 23Cr | - | ||
+48.39% | 78TCr | C+ | ||
-6.13% | 35TCr | C+ | ||
+20.61% | 33TCr | B- | ||
+10.00% | 30TCr | C+ | ||
+18.87% | 25TCr | B+ | ||
-1.96% | 22TCr | A+ | ||
+11.11% | 21TCr | B- | ||
+5.80% | 16TCr | C+ | ||
-2.50% | 16TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- A003220 Stock
- Ratings Daewon Pharmaceutical Co., Ltd.